Acute hemodynamic effects of bufuralol: a beta-adrenoceptor blocking drug with vasodilatory effects.
Simultaneous hemodynamic and equilibrium radionuclide function measurements were performed at rest and during exercise before and 75 min after oral administration of 30 mg bufuralol, a nonselective beta-adrenoceptor blocking drug, in 10 patients with stable angina pectoris. Acute beta-blockade with bufuralol resulted in a reduction of exercise-stimulated heart rate, Systolic blood pressure, and cardiac index. There was, however, also a fall in diastolic blood pressure and end-diastolic volume index, and an improved global left ventricular ejection fraction, without a change in total vascular resistance, suggesting an acute vasodilator effect. regional analysis revealed that this beneficial effect was particularly present in ischemic segments of the left ventricular wall where regional function increased. Thus, bufuralol is a beta-adrenoceptor blocking agent with additional peripheral vasodilating properties.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000787:Angina Pectoris / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D004983:Ethanolamines / Q000494:pharmacology* / Q000627:therapeutic use; D006334:Heart Function Tests; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D014665:Vasodilator Agents; C010831:bufuralol